The GLP-1 Nutrition Gap: What 461,382 Patient Records Actually Show

Researchers followed the claims records of 461,382 adults who started a GLP-1 medication. Within twelve months, 22.4 percent had a nutritional deficiency formally diagnosed. Vitamin D accounted for most of it, and three percent were diagnosed with muscle loss inside the same year.

It is a peer-reviewed retrospective analysis, and it is the largest count we have of how often these diagnoses actually get recorded after someone starts a GLP-1. It was also funded by Abbott, which manufactures oral nutritional supplements, and eight of its ten authors are Abbott employees. That does not make the numbers wrong, and I am citing it anyway — but it is the same interest I flag against the protein study further down, and you should weigh both the same way.

What the study measured — and why the real number is probably higher

The analysis, published in Obesity Pillars by Butsch and colleagues, covered 461,382 adults newly prescribed a GLP-1 receptor agonist between July 2017 and December 2021. Four in five had type 2 diabetes, and the most-prescribed drug in the cohort was dulaglutide, which is not a weight-loss product — so this describes a diabetes population, not someone taking Wegovy purely to lose weight.

The headline cohort had no control group. The authors say so plainly: the primary analysis “did not include a control group of non–GLP-1RA users,” so its incidence “cannot be directly compared to background rates.” A separate and much smaller propensity-matched analysis — 4,505 patients per arm — did make that comparison, and it is the one that shows an effect: at twelve months, 18.6 percent of GLP-1 patients had a nutritional deficiency diagnosed against 16.5 percent on metformin alone, and vitamin D deficiency ran 10.9 percent against 9.2. Both differences are statistically significant and both are about two percentage points. Nutritional anaemia and muscle loss did not differ significantly at all.

That distinction matters more than anything else on this page. The 22.4 percent tells you how often these diagnoses appear in this population. It does not tell you how much of that the drug added.

Now the detail that changes how you should read the headline. Patients who saw a dietitian within six months were diagnosed with deficiencies more often, not less — 18.5 percent versus 12.2 percent, and 29.8 versus 21.8 percent at a year.

The people who got looked at were the people who got found. Everyone else was simply never tested.

A dietitian visit does not cause a deficiency. It causes the deficiency to be noticed. Every number in that chart is a recorded diagnosis, which means somebody ordered a test, which means 22.4 percent is a floor rather than a ceiling. The quiet implication is that if you are on a GLP-1 and nobody has checked your bloods, you are not in the reassuring group — you are in the untested one.

Does the drug deplete vitamins, or does eating less?

This distinction matters, because the answer determines what actually helps.

GLP-1 receptor agonists slow gastric emptying and blunt appetite. There is no established mechanism by which they bind, chelate, or destroy micronutrients. The most straightforward route to a deficiency is much more ordinary: you eat considerably less food for months, and food is where nutrients come from. Nausea and food aversions narrow the diet further, often away from exactly the foods that carry the most nutrition per bite.

It is worth being precise about the limits here. This was an observational analysis of claims data. It establishes that deficiencies were diagnosed more often in GLP-1 users than in matched controls. It does not establish the mechanism, and no honest reading of it can.

The bigger gap, and nobody is selling a gummy for it

The search results for GLP-1 nutrition are almost entirely about micronutrients, because micronutrients are what there is a product to sell. The larger problem is more boring.

In 2025 four professional bodies — the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society — issued a joint advisory on nutrition during GLP-1 therapy. It notes that higher protein targets — 1.2 to 1.6 grams per kilogram per day — “have also been proposed” during active weight reduction, against a general adult reference intake of 0.8, and it recommends resistance training to protect muscle and bone. Read the basis carefully, because the advisory is emphatic about it: for people with obesity it is “unclear whether these goals should be based on actual body weight, corrected (adjusted or ideal) body weight, or fat-free mass, as the use of actual weight can significantly overestimate protein requirements.” The survey below calculated needs on adjusted body weight, not the number on the scale.

Against that target, a cross-sectional survey of 60 GLP-1 users found only 43 percent reaching even the 1.2 g/kg floor. Ten percent reached 1.6 g/kg. Five percent reached 2.0.

Treat those exact percentages as indicative rather than settled, for two reasons we would rather state than bury. It is a small study — 60 adults, using self-reported three-day food records. And it was funded by GNC Holdings, with all five authors employed by the company. That does not make the finding wrong, but a supplement manufacturer publishing evidence that its customers are short on protein is exactly the kind of interest a reader deserves to weigh, and this article would be poorly placed to omit it.

The direction, at least, lines up with something independent: the muscle-loss finding in the much larger claims analysis, where three percent of patients received a muscle-loss diagnosis within a year. A formal diagnosis is a high bar; the number of people quietly losing lean tissue without one is necessarily larger.

Protein is also the one variable here you can move immediately, without a blood test, a prescription, or a purchase.

Why hair loss is not the vitamin story it is sold as

Hair loss is one of the most searched GLP-1 side effects, and an entire product category has grown up around it. The evidence supports the side effect. It does not support the product.

A scoping review of alopecia associated with GLP-1 receptor agonists collected the trial-level reports: around 7 percent of participants in SURMOUNT-3 (20 of 287) and a similar share in OASIS 1 (23 of 334). The FDA adverse event system holds more than a thousand spontaneous reports, though the review is careful to note that spontaneous reporting cannot produce a real incidence rate.

The mechanism the reviewers put forward is not a nutrient deficiency. It is rapid weight loss itself — acute metabolic stress triggering telogen effluvium, the same temporary shedding well documented after bariatric surgery, serious illness, and aggressive calorie restriction. In the one study that classified cases in detail, 35 patients carried 42 separate alopecia diagnoses between them — 19 of them androgenetic and 10 telogen effluvium. Some patients therefore had more than one diagnosis, and the androgenetic share suggests GLP-1s may also unmask pattern hair loss in people already predisposed to it.

What not to take together

One question comes up constantly: what should you avoid taking alongside a GLP-1? The honest answer is that the sharper conflicts are usually between your supplements, not between a supplement and the drug.

Calcium and iron compete directly, and taking them together substantially reduces iron absorption — which matters more than usual if hair thinning is already a worry. Vitamin D is fat-soluble and does better with a meal containing some fat, which is a real constraint when meals have become small and low-fat by accident. And because GLP-1s slow gastric emptying, anything taken with food sits longer before it is absorbed. You can check a specific combination in our supplement stack checker, and the nutrient pairings pages cover the individual conflicts.

What to actually do about it

1. Ask for bloods rather than guessingVitamin D, B12, ferritin and a full blood count are inexpensive and they replace speculation with a number. Given that the diagnosed rate rose sharply among people who were actually assessed, this is the single highest-value step — and it is the one no supplement bundle can do for you.
2. Put protein first in the meal, literallyWhen appetite is suppressed, the first few bites are the only ones you are guaranteed to finish, so eat the protein part of the plate first. Work the actual target out with your prescriber or a dietitian rather than off your bathroom scale: these targets are calculated on adjusted body weight, and using your actual weight can significantly overestimate what you need. If you have kidney disease, do not raise protein on your own — protein targets change materially in chronic kidney disease, and 5.5 percent of the patients in the claims analysis had it.
3. Treat vitamin D as the likeliest gapIt was the most frequently diagnosed deficiency by a wide margin. Take it with the fattiest meal of your day, and confirm the dose against a test rather than a label.
4. Add resistance training if you canProtein preserves lean mass considerably better when there is a reason for the body to keep it. Only about half of GLP-1 users in that survey reported exercising more after starting.
5. Track density, not just caloriesA 1,200-calorie day can be nutritionally excellent or nutritionally empty, and the calorie total cannot tell them apart. When you are eating half as much, what each meal contains stops being a detail.

Where Tavita fits, and where it does not

Tavita will show you what your intake actually looks like against reference amounts — the protein target in grams, and where vitamin D, iron and B12 are running against them. On a GLP-1, where intake drops sharply and quietly, that visibility is the difference between noticing a gap in week three and being diagnosed with one in month nine.

What it will not do is measure your blood. A food log is an estimate of intake, not of status, and the two come apart — particularly for vitamin D, where sun exposure and absorption matter as much as diet. Nothing here replaces a test or your prescriber. It tells you where to look.

Common questions